Jonathan Bornstein - 10 Mar 2025 Form 4 Insider Report for Amprius Technologies, Inc. (AMPX)

Reporting relationship: President of Amprius Lab
Issuer ticker: AMPX
Reported as of: 10 Mar 2025
Net transaction value: +$3,402
SEC form: 4
Accepted by SEC: 12 Mar 2025, 17:14:58 UTC
Prior SEC filing: 24 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Sandra Wallach, attorney-in-fact on behalf of Jonathan Bornstein

Key filing fact

Jonathan Bornstein filed Form 4 for Amprius Technologies, Inc. (AMPX) on 12 Mar 2025.

Key facts

This page summarizes Jonathan Bornstein's Form 4 filing for Amprius Technologies, Inc. (AMPX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Mar 2025, 17:14.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: +$3,402.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMPX transaction

Common stock

Options Exercise

Transaction value: $3,402
Shares: +3,471
Change %: +0.83%
Price: $0.9800
Shares after: 422,668
Date: 10 Mar 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMPX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -3,471
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 10 Mar 2025
Ownership: Direct
Underlying class: Common stock
Underlying amount: 3,471
Exercise price: $0.9800

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Includes 419,197 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.